BI 1831169

AXP000120.1 · Oncolytic virus

Platform
VSV-GP (vesicular stomatitis virus with LCMV glycoprotein)
Originator
Viratherapeutics
Sponsor
Boehringer Ingelheim

Names

NameTypeSource
BI 1831169preferred name, codecurator, press
VSV-GP ambiguoussynonympress

Virus

Role
Oncolytic
Family
Rhabdoviridae
Virus
vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
Strain
VSV-GP chimera
Replication
replicating
Modifications
VSV G protein replaced by lymphocytic choriomeningitis virus glycoprotein (GP)
Route
intravenous, intratumoral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07176975A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced CancersSuspendedPhase 12027-08-032028-12-1946Solid Tumors
NCT05155332A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)SuspendedPhase 12022-03-282028-07-18190Solid Tumors

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 35699077Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.Future oncology (London, England)2022cited by trial NCT05155332

Other papers

Preclinical studies, reviews and other papers that name it.

No confirmed other papers yet.

Unconfirmed matches (22)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 41766922The oncolytic vesicular stomatitis virus VSV-GP shows profound oncolytic activity in NUT-carcinoma cell lines.Molecular therapy. Oncology2026name in title: VSV-GP
PMID 41893803Protein Priming Followed by a Replication-Competent VSV-GP Vector Boost Induces Sustained Immune Control in Therapeutic Hepatitis B Vaccination.Vaccines2026name in title: VSV-GP
PMID 42191950An ex vivo permissivity assay to assess replication of the oncolytic virus VSV-GP in patient-derived tumor samples.Oncogene2026name in title: VSV-GP
PMID 40013517Molecular Pathology Methods to Characterize Biodistribution and Pharmacodynamics of the Oncolytic Virus VSV-GP in a Nonclinical Tumor Model.Toxicologic pathology2025name in title: VSV-GP
PMID 40083959Characterization of VSV-GP morphology by cryo-EM imaging and SEC-MALS.Molecular therapy. Methods & clinical development2025name in title: VSV-GP
PMID 40521092Perfusion process with tangential flow filtration for oncolytic VSV-GP production.Frontiers in bioengineering and biotechnology2025name in title: VSV-GP
PMID 40835316Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype.Journal for immunotherapy of cancer2025name in title: VSV-GP
PMID 41282468Newly identified oncolytic VSV-GP-specific CD8+ T cell epitopes for monitoring of anti-viral immune responses in the BALB/c mouse model.Molecular therapy. Oncology2025name in title: VSV-GP
PMID 41398167Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits.NPJ vaccines2025name in title: VSV-GP
PMID 38916347Absolute quantification of viral proteins from pseudotyped VSV-GP using UPLC-MRM.Microbiology spectrum2024name in title: VSV-GP
PMID 39203993Characterization of the Anti-Viral and Vaccine-Specific CD8+ T Cell Composition upon Treatment with the Cancer Vaccine VSV-GP.Vaccines2024name in title: VSV-GP
PMID 39703791Repeated harvest enables efficient production of VSV-GP.Frontiers in bioengineering and biotechnology2024name in title: VSV-GP
PMID 36700123Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication.Molecular therapy. Methods & clinical development2023name in title: VSV-GP
PMID 37086948Therapeutic Efficacy of a VSV-GP-based Human Papilloma Virus Vaccine in a Murine Cancer Model.Journal of molecular biology2023name in title: VSV-GP
PMID 36394051Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP.Frontiers in bioengineering and biotechnology2022name in title: VSV-GP
PMID 36741416Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP.Frontiers in immunology2022name in title: VSV-GP
PMID 31530903The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.British journal of cancer2019name in title: VSV-GP
PMID 31921191Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.Frontiers in immunology2019name in title: VSV-GP
PMID 29498639The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.Viruses2018name in title: VSV-GP
PMID 29696636Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer.International journal of cancer2018name in title: VSV-GP
PMID 27738655Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.Molecular therapy oncolytics2016name in title: VSV-GP
PMID 24554655VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.Journal of virology2014name in title: VSV-GP

Notes

Chimeric VSV whose G protein is replaced by the LCMV glycoprotein (VSV-GP), reducing neurotoxicity. Viratherapeutics was acquired by Boehringer Ingelheim in 2018. Given both intravenously and intratumorally in study 1456-0001.

How to cite

BI 1831169 (AXP000120.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000120.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.